Takeda’s TAK-881 matches HYQVIA’s IgG exposure (99.67%) while cutting infusion volume roughly in half
Takeda reported that its Phase 2/3 trial TAK-881-3001 showed TAK-881 produced essentially the same immunoglobulin G (IgG) exposure as HYQVIA—a…
Takeda reported that its Phase 2/3 trial TAK-881-3001 showed TAK-881 produced essentially the same immunoglobulin G (IgG) exposure as HYQVIA—a…